Viome Life Sciences, Inc., the US precision health company known for its diagnostic testing and personalised nutrition recommendations, and Ezaki Glico have announced the launch of mRNA HEALTH TRACKER®, Japan's first personalised health service built on gut bacteria mRNA analysis.
The Glico partnership marks the first international application of Viome’s partnership model, which is designed to pair Viome’s precision health intelligence platform with established companies that have complementary capabilities and trusted relationships with consumers.
Under this model, Viome provides the technology and infrastructure behind the personalised health experience, testing kit logistics, RNA analysis, and proprietary AI models. Partners bring their own strengths, such as product formulation, distribution, and additional consumer guidance. Together, the companies can translate individual biological data into actionable products and services that improve public health on the personal level.
The Japan launch adds to Viome's expanding international footprint, as demand grows worldwide for personalised, science-based approaches to nutrition and gut health. Glico plans to roll out this service to 50,000 customers by 2030, focusing on test distribution and data collection for health-conscious customer cohorts this year.
